ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

ClinicalTrials.gov ID: NCT02161406

Public ClinicalTrials.gov record NCT02161406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.

Study identification

NCT ID
NCT02161406
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dinesh Khanna, MD, MS
Other
Enrollment
88 participants

Conditions and interventions

Interventions

  • Abatacept Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2014
Primary completion
Sep 11, 2018
Completion
Oct 16, 2018
Last update posted
Feb 16, 2020

2014 – 2018

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Arthritis Associates of Southern California Los Angeles California 90045
University of California- Los Angeles Los Angeles California 90095
Stanford University Redwood City California 94063
Georgetown University Washington D.C. District of Columbia 20009
Northwestern University Chicago Illinois 60611
Harvard Mass General Boston Massachusetts 02116
Boston University Boston Massachusetts 02118
University of Michigan Ann Arbor Michigan 48109
University of Minnesota Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Rutgers University Clinical Research Center New Brunswick New Jersey 08831
Steffens Scleroderma Center Albany New York 12203
NorthWell Health Great Neck New York 11021
Hospital for Special Surgery New York New York 10021
Columbia University New York New York 10032
Cleveland Clinic Cleveland Ohio 44195
Ohio State University Medical Center Columbus Ohio 43221
University of Pennsylvania Philadelphia Pennsylvania 19104
University of Pittsburgh Pittsburgh Pennsylvania 15261
Medical University of South Carolina Charleston South Carolina 29425
University of Texas Health Center at Houston Houston Texas 77030
University of Utah Salt Lake City Utah 84132
Swedish Health Services Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02161406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02161406 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →